



2021 AMR Preparedness Index

Launch Webinar

June 23, 2021

7am-8:15am EDT | 13-14.15h CEST | 8-9:15pm JST

Supported by







Agenda

Торіс	Speakers		
Welcome & Introductions	Mike Hodin, CEO, GCOA		
Comments by Dr. Neil J. Clancy, IDSA	Dr. Neil J. Clancy, AMR Committee, IDSA		
Comments by MEP Tiemo Wölken, Germany	MEP Tiemo Wölken, Germany		
Comments by James Anderson, Executive Director – Global Health, IFPMA	James Anderson, Executive Director – Global Health, IFPMA		
Presentation of the 2021 AMR Preparedness Index	Susan Wile Schwarz, Director of Communications, GCOA		
 Discussion of key themes with: Anand Anandkumar Christine Årdal Dr. Neil J. Clancy Dr. Norio Ohmagari Tiemo Wölken 	Moderated by Mike Hodin, CEO, GCOA		
Concluding Comments	GCOA, IDSA		









Global Coalition on Aging

Comments





Medicine, University of Pittsburgh School of Medicine; and AMR Committee, Infectious Diseases Society of America

Dr. Neil J. Clancy, Chief, Infectious Diseases Section, VA

Pittsburgh Health Care System; Associate Professor of










Presentation of the 2021 AMR Preparedness Index







Countries Evaluated

Top 12 G20 Economies by GDP

United States
European Union**
China
Japan
Germany
India

- United Kingdom
- France
- Italy
- Brazil
- Canada
- South Korea



Index Advisory Council

Members of the AMR Preparedness Index Advisory Council

Helen Boucher, Director, Tufts Center for Integrated Management of Antimicrobial Resistance;
Treasurer, Infectious Diseases Society of America
Gemma Buckland Merrett, Science Lead Drug Resistant Infections, Wellcome Trust
John Rex, Chief Medical Officer & Director, F2G, Ltd; Operating Partner, Advent Life Sciences

Ryoji Noritake, CEO, Health and Global Policy Institute, leader of Japan AMR Task Force **Zhang Zhenzhong**, Secretary General, China Health Economics Association

Ninie Wang, Founder and CEO, Pinetree Care Group

Alex Kalache, President, International Longevity Centre-Brazil and co-President; Global Alliance of International Longevity Centres


Ramanan Laxminarayan, Founder and Director, Center for Disease Dynamics, Economics & Policy

Dame Sally Davies, UK Special Envoy on Antimicrobial Resistance



Index Drafting & Development

Insights from Research Pillars Shape Final Narrative





Policy Evaluation Framework – Categories & Indicators

NATIONAL STRATEGY	 National Action Plan Research Investment Working Groups, etc. 	AMR & THE ENVIRONMENT	 Environment in AMR NAPs Antimicrobial Use in Animals Responsible Manufacturing Disposal
AWARENESS & PREVENTION	 Information and Training Vaccine Surveillance and Monitoring Healthcare Setting 		 Push Incentives Pull Incentives Innovation Support R&D Investment IP Protections
ACCESS	 General Access and Quality Availability Affordability 		 Research Infrastructure Development and Partnership Efforts Novel Valuation Methods
APPROPRIATE & RESPONSIBLE USE	 Healthcare System Utilization Usage 	COLLABORATIVE ENGAGEMENT	 NGO-Supported Engagement Partnerships Global Collaborative Actions Global Coalition on Aging 8

How to Use the 2021 AMR Preparedness Index









A benchmark against which to monitor progress and hold decisionmakers accountable A tool to support advocacy, policy, and research at a global and country levels A resource of best practices to successfully address AMR at the country and global levels A call for collaboration within and among the AMR and aging advocacy communities




Priorities for Action & Overall Scores

- Strengthen and fully implement national AMR strategies
- Raise awareness of AMR and its consequences, while targeting prevention opportunities
- Bolster surveillance and leverage data across AMR efforts
- Enable a restructured antimicrobial marketplace to stimulate innovation
- Promote responsible and appropriate use of antibiotics
- Enable reliable and consistent access to needed and novel antimicrobials
- More effectively integrate the One Health approach, including environmental considerations, into national strategies
- Better engage with other governments, third-party organizations, and advocacy groups

Overall Scores

The graph below provides a holistic view of each country's scores. It highlights categories where countries have the most opportunity for improvement and areas where countries are demonstrating best or "better" practices. Further scoring visuals for specific categories are provided throughout the Index.

The category scores have been equally weighted – with a maximum of approximately 14% per category – to construct an overall Index score on a 100-point scale. For all countries, there is clearly much room for improvement, though some trends have emerged: most countries (bar the UK and US who fare slightly better) perform especially poorly in the National Strategy, Innovation, and Collaborative Engagement categories, with scores in the Innovation category being the lowest overall; all countries perform insufficiently in the Awareness & Prevention and Access categories, with India lagging behind; and more developed countries tended to fare better in the Appropriate & Responsible Use category.



Overall Scores with Category Contributions

National Strategy: Key Findings & Scores


- Countries are not making adequate investments to combat the AMR threat
- AMR is **not a political priority** in most countries
- NGOs, advocacy groups, and patient organizations are often missing from national conversations
- The global nature of antimicrobial resistance (AMR) has discouraged countries from taking bold, unilateral actions
- Many countries are insufficiently engaged with the global AMR community
- COVID-19 has virtually halted implementation of national AMR strategies



National Strategy

Evaluates the high-level policies, commitments, and investments that national governments have undertaken to combat AMR.

National Strategy Country Comparison



National Strategy: Calls to Action

→ Governments must make **bolder financial investments** to tackle AMR

→ Governments should **better engage NGOs**, advocacy groups, and the patient community in developing and implementing NAPs and other AMR initiatives

→ Governments should develop more ambitious NAPs and provide sufficient funding to achieve goals

→ Governments should lean into AMR initiatives and actions now



Awareness & Prevention: Key Findings & Scores


- Public awareness across most countries remains low, driving overuse
- Countries' vaccination programs are not being fully leveraged
- Weak, insufficient healthcare systems and inadequate public health infrastructure are major barriers
- Most countries have dedicated surveillance and monitoring systems, but the degree of sophistication and transparency varies
- In many countries, data collected in monitoring systems are inadequate and do not drive decision making
- AMR training for medical professionals is available but needs strengthening
- Despite ongoing challenges, many governments and NGOs have successfully implemented awareness campaigns



Awareness & Prevention

Assesses the level of commitment within countries to fund and facilitate efforts to increase awareness among stakeholder groups and improve mechanisms that can prevent and monitor AMR.

Awareness & Prevention Country Comparison



Awareness & Prevention: Calls to Action

 \rightarrow Governments should strengthen efforts to improve patient awareness

→ Governments should bolster training requirements and program funding for medical professionals and medical trainees for IPC and beyond

 \rightarrow Governments should redouble vaccination efforts

→ Governments should improve sanitation in healthcare systems and public health infrastructure along WHO IPC guidelines

 \rightarrow Governments should increase surveillance and monitoring commitments


Innovation: Key Findings & Scores


- There is a consensus that antimicrobials are not fairly valued in most countries and that reforms are needed
- No countries have effective pull incentives
- Most countries have stalled on high-level discussions
- Very few countries have erected the research infrastructure necessary to support the development of AMR diagnostics, surveillance technologies, and new antimicrobials
- Most countries have made measurable progress implementing push incentives



Innovation

Quantifies governments' commitments to foster and support AMR innovation, especially in areas of greatest opportunity, including novel valuation and pull mechanisms.





Innovation: Calls to Action

→ Governments should implement pull incentive programs within the next three years

→ Governments should increase investments in AMR innovations for surveillance and diagnostics

Access: Key Findings & Scores

- Access to novel antimicrobials is limited in all but a few countries
- Patients continue to struggle accessing older (non-novel) antimicrobials
- Government delays in moving drugs to a reimbursement list can also stymie access



Access: Calls to Action

→ Governments should expedite access by reducing regulatory hurdles and accelerating government adoption

→ Governments should make the availability of novel antimicrobials a national priority

→ Governments should establish or support sustainable systems for manufacturing and dispensing antimicrobials across the supply chain



Appropriate & Responsible Use: Key Findings & Scores


- Over-the-counter availability compounds AMR challenges
- For drugs that require a prescription, overprescribing is a problem
- General practitioners lack tools and resources needed for proper diagnosis
- Patients clamor for antimicrobials
- Governments fall short on monitoring and oversight
- Hospitals outperform outpatient settings, but stewardship efforts are generally still inadequate in many countries
- Some countries are taking additional action to curb overprescription



Appropriate & Responsible Use

Assesses governments' efforts to reduce misuse and overuse of antimicrobials and promote rational diagnosis.

Appropriate & Responsible Use Country Comparison



Appropriate & Responsible Use: Calls to Action

→ Governments should provide better access to diagnostic tools for general practitioners

→ Governments should improve enforcement and administration of existing laws

→ Governments should provide guidance and funding to strengthen stewardship in inpatient settings and to implement stewardship in outpatient settings

→ Governments should support expansion and training of the medical workforce necessary to promote appropriate antibiotic use

AMR & the Environment: Key Findings & Scores


- The principles of the One Health approach continue to gain traction worldwide and are being acknowledged in environmental policies and private sector actions
- More AMR environmental research is required, and non-human uses remain critical
- Policies and implementation are limited, but some stakeholders are taking action



AMR & the Environment

Examines the ways in which national governments are attempting to manage antimicrobials throughout their life cycle: production, usage in the environment, and disposal.

AMR & the Environment Country Comparison



AMR & the Environment: Calls to Action

→ Governments should better integrate environmental controls in their National Actions Plans

→ Governments should continue to integrate the One Health approach and give equal weight to environmental components

→ Governments should support enhanced data collection to improve global understanding of the impact of antimicrobials in the environment

Collaborative Engagement: Key Findings & Scores


- Country-level NGOs, advocacy groups, and patient organizations play a critical role in advancing AMR initiatives in four core areas:
 - Innovation
 - Research
 - Surveillance
 - Monitoring and awareness



Collaborative Engagement

Captures how effectively national governments are facilitating collaborative engagement to address AMR.

Collaborative Engagement Country Comparison



Collaborative Engagement: Calls to Action

→ Governments should provide more direct support for research institutions and working groups, including establishing and growing clinical trial networks

Governments should partner with NGOs, advocacy groups, and patient organizations on pilot programs

→ Countries should invest in training the next generation of AMR researchers and clinicians to support clinical trials




Conclusion

The AMR crisis is here, and national governments must step up now to address existing threats

If countries fail to take needed action, the AMR crisis will become a full-blown humanitarian catastrophe, threatening the miracle of human longevity

With concerted action, progress *can* be made

Overall Scores with Category Contributions





Discussion of Key Themes





Anand Anandkumar Bugworks Research

Christine Årdal EU-JAMRAI



Dr. Neil J. Clancy VA Pittsburgh Health Care System, University of Pittsburgh

School of Medicine, IDSA, US



Dr. Norio Ohmagari

National Center for Global Health and Medicine Hospital, Japan



Tiemo Wölken Member of European Parliament, Germany





Concluding Comments



